King Luther Capital Management Corp Grows Holdings in Pfizer Inc. (NYSE:PFE)

Key Points

• King Luther Capital Management Corp increased its holdings in Pfizer Inc. by 6.5%, owning nearly 2.7 million shares worth approximately $68.4 million as of the most recent SEC filing.
• Pfizer reported earnings per share (EPS) of $0.78 for the last quarter, exceeding analyst expectations of $0.58, and its revenue increased by 10.3% year-over-year.
• The company declared a quarterly dividend of $0.43 per share, resulting in an annualized dividend yield of 7.0%, with a payout ratio of 91.49%.

King Luther Capital Management Corp grew its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 6.5% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 2,698,932 shares of the biopharmaceutical company's stock after acquiring an additional 163,847 shares during the period. King Luther Capital Management Corp's holdings in Pfizer were worth $68,391,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the business. William B. Walkup & Associates Inc. raised its stake in shares of Pfizer by 1.2% during the fourth quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock valued at $1,044,000 after acquiring an additional 454 shares during the last quarter. Members Trust Co raised its stake in shares of Pfizer by 2.1% during the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock valued at $587,000 after acquiring an additional 467 shares during the last quarter. Sutton Place Investors LLC raised its stake in Pfizer by 5.6% during the first quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock worth $224,000 after buying an additional 472 shares during the last quarter. Bellevue Group AG raised its stake in Pfizer by 0.3% during the fourth quarter. Bellevue Group AG now owns 141,560 shares of the biopharmaceutical company's stock worth $3,756,000 after buying an additional 485 shares during the last quarter. Finally, Gould Capital LLC raised its stake in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on PFE shares. Berenberg Bank lowered their target price on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research note on Thursday, May 29th. Wolfe Research lifted their target price on shares of Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a research note on Wednesday, April 30th. UBS Group lifted their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Leerink Partners lowered their target price on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a research note on Wednesday, April 30th. Finally, Morgan Stanley lifted their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 6th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $28.12.

Pfizer Stock Up 1.6%

Shares of NYSE PFE traded up $0.39 during mid-day trading on Wednesday, reaching $25.04. 27,130,985 shares of the company's stock traded hands, compared to its average volume of 45,751,281. The stock has a market cap of $142.34 billion, a P/E ratio of 13.32, a PEG ratio of 0.88 and a beta of 0.52. The business has a 50-day simple moving average of $24.49 and a 200 day simple moving average of $24.47. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business's revenue was up 10.3% on a year-over-year basis. During the same period last year, the company earned $0.60 earnings per share. On average, analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.